Webinar: Contemporary Pharmacotherapy for OAB 2020: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2020)

July 2, 2020

Course Director: Eric S. Rovner, MD

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 6th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.


The American Urological Association would like to thank the following companies for providing independent educational grants:

  • Astellas
  • Medtronic

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

Upon completion of this activity, course participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).
  2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.
  3. State the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
  4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
  5. Describe potential future pharmacological pathways and therapies for OAB.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
07/02/2020 - 7:00pm
Event ends: 
07/02/2020 - 8:30pm

Scientific Agenda



Patient Expectations and Goals

Eric S. Rovner, MD

OAB Guidelines:  SUFU/AUA

Eric S. Rovner, MD

Physiological/Pharmacological Principles underlying OAB

Christopher Chapple, BSc, MBBS, MD, FRCS (Urol), FEBU, FCSHK (Hon)

Pharmacotherapy of OAB in 2020 

Alan J. Wein, MD, PhD (hon), FACS

Combination Pharmacotherapy for OAB

Christopher Chapple, BSc, MBBS, MD, FRCS (Urol), FEBU, FCSHK (Hon)

Future Directions in OAB Pharmacotherapy

Alan J. Wein, MD, PhD (hon), FACS


Eric S. Rovner, MD

Contemporary Pharmacotherapy for OAB 2020: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2020) will be held virtually on Thursday, July 2 at 7 PM EST.


  1. Click the "Register" tab.
  2. If prompted, click “update your profile”. Otherwise, click “Take Course”.
  3. Click “Start” under Live Webinar in the Course Progress pane.
  4. Click "Join Webinar."

Education Council Disclosures

PDF icon EC Disclosures _June 1 20 through Dec 31 20_2.pdf

AUA Office of Education Staff has nothing to disclose.


Course Director(s)



The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA Participant Information and Policies


The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.


Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.


The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

To join the webinar:

  1. Click on the TAKE COURSE button.
  2. Click “Start” under Live Webinar in the Course Progress pane.
  3. Click "Join Webinar."